Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation in patients with cancer
In this week's episode, we’ll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who receive stem cell transplants, and a cell death process that may help account for increased thromboembolic risk in patients receiving cancer chemotherapy.
Featured Articles:
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
Emapalumab therapy for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.